Navigation Links
Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
Date:6/3/2009

PARIS and BRISBANE, California, June 3 /PRNewswire-FirstCall/ --

- Data Highlighted in Plenary Session of 2009 American Society of Clinical Oncology Annual Meeting

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and its fully owned subsidiary, BiPar Sciences, today announced results from a randomized Phase 2 clinical trial of BSI-201, a poly ADP-ribose polymerase (PARP) inhibitor, in combination with gemcitabine and carboplatin (GC) chemotherapy, in patients with metastatic triple-negative breast cancer (TNBC). BSI-201 is a novel investigational agent that acts by inhibiting PARP1, an enzyme that repairs DNA damage.

In this study, 116 women with metastatic TNBC, defined as tumors lacking expression of estrogen and progesterone receptors and without overexpression of HER2, were randomly assigned to receive GC in combination with the investigational agent BSI-201 or GC alone. Patients assigned to receive chemotherapy without BSI-201 were allowed to receive BSI-201 at the time of disease progression.

The primary study endpoint was the rate of clinical benefit, defined as complete or partial response or stable disease of at least 6 months. Secondary study endpoints included progression-free survival, overall survival and safety.

Approximately 62 percent of patients receiving BSI-201 in combination with GC showed clinical benefit, compared with 21 percent in the group receiving chemotherapy alone (p= 0.0002). Tumor response (complete or partial response) was observed in 48 percent of patients who received BSI-201 combined with chemotherapy, whereas patients receiving chemotherapy alone showed a response rate of 16 percent. Women who received BSI-201 had a median progression-free survival of 6.9 months and overall survival of 9.2 months compared with 3.3 and 5.7 months, respective
'/>"/>

SOURCE Sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
2. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-CXCR4 Antibody, MDX-1338
3. D-Pharm Submits Investigational New Drug Application and Special Protocol Assessment to the FDA for Phase III Trial of DP-b99 in Acute Stroke Patients
4. Investigational Genetic Test May Help Address Common Problems in Prostate Cancer Diagnosis
5. Glycotex Investigational Compound GLYC-101 Achieves Accelerated Wound Closure Based on Interim Analysis
6. Premier Research Announces Milestone Investigational New Drug Application
7. Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
8. Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis
9. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
10. ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410
11. Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... NEW YORK , Sept. 1, 2014 /PRNewswire/ ... report is available in its catalogue:  Drug ... http://www.reportlinker.com/p02349116/Drug-Discovery-Technologies---A-Global-Market-Overview.html ... diseases, such as cancer requires extensive expenditure, in ... first step in designing a new drug involves ...
(Date:8/29/2014)... 2014 /PRNewswire-iReach/ -- Market Research Report on Global ... a professional and in-depth market survey on ... The report firstly reviews the basic information of ... manufacturing technology. The report then explores global and ... their product specification, capacity, Production value, and market ...
(Date:8/29/2014)... Aug. 29, 2014 Pomerantz LLP has filed ... the "Company") (NASDAQ: EDAP ) and certain ... States District Court, Southern District of New ... behalf of a class consisting of all persons or ... and July 30, 2014, inclusive (the "Class Period"). This class ...
Breaking Medicine Technology:Drug Discovery Technologies - A Global Market Overview 2Drug Discovery Technologies - A Global Market Overview 3Drug Discovery Technologies - A Global Market Overview 4Drug Discovery Technologies - A Global Market Overview 5Drug Discovery Technologies - A Global Market Overview 6Drug Discovery Technologies - A Global Market Overview 7Drug Discovery Technologies - A Global Market Overview 8Drug Discovery Technologies - A Global Market Overview 9Drug Discovery Technologies - A Global Market Overview 10Drug Discovery Technologies - A Global Market Overview 11Drug Discovery Technologies - A Global Market Overview 12Drug Discovery Technologies - A Global Market Overview 13Drug Discovery Technologies - A Global Market Overview 14X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against EDAP TMS S.A. and Certain Officers - EDAP 3
... Epocal, Inc., a leading edge provider of point of ... and Drug Administration (FDA) clearance to market its new lactate ... the epoc System are used to evaluate acid-base status and ... of the blood).  The addition of lactate to the epoc ...
... , ANN ARBOR, Mich. , June 15 ... announced that its wholly-owned CLIA-certified clinical testing subsidiary, HartLab, ... a full array of microbiology testing.  Adeona believes that ... HartLab,s revenues in the current quarter and beyond and ...
Cached Medicine Technology:Epocal Announces FDA Clearance of Lactate Test 2Adeona Announces HartLab Expansion Into Microbiology Testing Services 2Adeona Announces HartLab Expansion Into Microbiology Testing Services 3Adeona Announces HartLab Expansion Into Microbiology Testing Services 4Adeona Announces HartLab Expansion Into Microbiology Testing Services 5
(Date:9/1/2014)... September 01, 2014 An operating theatre ... hospital for performing surgical operations. An operating room comprises ... surgical booms, operating room lights, imaging displays as well ... report by Transparency Market Research, a U.S.-based market research ... reach USD 4.5 billion by 2019. , According ...
(Date:9/1/2014)... HealthDay Reporter FRIDAY, Aug. ... given to two American aid workers successfully cured a group ... researchers report. The drug, ZMapp, prompted recovery in all ... the medication until five days after infection. ZMapp even ... or even hours away from death, said study senior author ...
(Date:9/1/2014)... D.C. (PRWEB) September 01, 2014 The ... pleased to announce that Dawn Bazarko, DNP, MPH, RN, ... Fellows of the American Academy of Nursing. They will ... MBA, RN-BC, CCM, FACHE, whose induction we reported last ... October 18, 2014, during the 2014 American Academy of ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Parties involved ... ahead to the litigation’s status conference in September, where ... be discussed in the Eastern District of Pennsylvania, Bernstein ... of status conferences posted on the Court’s website, the ... 2014 at 10:00 a.m. This is the latest of ...
(Date:9/1/2014)... August 31, 2014 Daily Gossip reveals ... resource and community that gives members access to thousands ... , This online resource aims to help both people ... as artists who are looking for inspiration in creating ... about Tattoo Me Now by visiting the official website ...
Breaking Medicine News(10 mins):Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 2Health News:Operating Room Equipment Market Study 2019 by Transparency Market Research 3Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Tattoo Me Now Review Reveals Unique Ideas for Tattoo Designs 2
... ARAY ), a global leader in the field of radiosurgery, ... Needham Life Sciences Conference in New York City, on Wednesday, June ... , A live webcast of the presentation will be available online ... http://www.accuray.com . The webcast replay ...
... to 25% drop in test scores, study found , THURSDAY, ... reason to be annoyed at other people,s cell phones, researchers ... ringtone can impair thinking, at least briefly. , Students unwittingly ... after a fellow "student,s" phone went off. , The finding ...
... to growing list of solutions available to help companies and ... , DEERFIELD, Ill., June 4 Knowledge and prevention are ... may look or feel healthy, you may not know about ... , , That is why Focused Health Solutions, a ...
... risk while ensuring accurate payments and compliance with Medicare standards , ... have ever wondered how to integrate Medicare Risk Adjustment with their ... latest release from Storan Technologies Inc. (STI). ... Merlin Medicare Risk Adjustment 6.0 (TM), a Web-based software solution ...
... June 4 Abbott (NYSE: ABT ) ... a New Drug Application (NDA) to the U.S. Food ... the treatment of mixed dyslipidemia, a combination of two ... "bad" cholesterol), high triglycerides and low HDL-cholesterol (the "good" ...
... , SUNNYVALE, Calif., June 4 - Cepheid (Nasdaq: ... for its symposium, "On-Demand HAI Testing: Good Medicine and ... 2009 Association for Professionals in Infection Control (APIC) annual ... - 10th. Cepheid,s GeneXpert(R) Systems and menu of molecular ...
Cached Medicine News:Health News:Accuray Incorporated to Present at Eighth Annual Needham Life Sciences Conference 2Health News:Stranger's Cell Phone Ring May Thwart Your Thinking 2Health News:Stranger's Cell Phone Ring May Thwart Your Thinking 3Health News:Focused Health Solutions Helps Make Preventative Health Screenings Simple and More Affordable 2Health News:Focused Health Solutions Helps Make Preventative Health Screenings Simple and More Affordable 3Health News:St. Louis Firm Brings Medicare Risk Adjustment to iPhone 2Health News:Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia 2Health News:Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia 3Health News:Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia 4Health News:Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia 5Health News:Cepheid Announces Symposium Program for 2009 Association for Professionals in Infection Control (APIC) Annual Conference 2Health News:Cepheid Announces Symposium Program for 2009 Association for Professionals in Infection Control (APIC) Annual Conference 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: